Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Pediatr Allergy Immunol ; 24(1): 75-83, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22882430

ABSTRACT

BACKGROUND: Hen's egg allergy affects young children and can cause severe allergic reactions. Avoidance results in dietary limitations and can affect the quality of life, especially in cases where potentially life-threatening reactions exist. Our objective was to desensitize children with moderate-severe IgE-mediated hen's egg allergy over a 6-month period, by introducing increasing and very gradual daily doses of raw hen's egg in order to enable the children to assume 25ml of this food, or to induce tolerance to the highest possible dose. The protocol foresaw the egg reintroduction in the home setting. METHODS: In this randomized, controlled open study, 20 hen's egg allergic children (10 in the active group) were admitted. A convincing history or a positive double-blind placebo-controlled food challenge confirmed the diagnosis. Oral desensitization was performed with increasing doses starting from 0.27 mg of hen's egg proteins (1 drop of raw hen's egg diluted 1:100). We adopted an original, mathematically calculated protocol in order to ensure a constant, daily increment of doses. RESULTS: 8/10 children (80%) in the active group achieved the daily intake of 25ml over a 6-month period. One child (10%) could tolerate up to 2ml/day while another child (10%) failed the desensitization. Six months after enrolment only 2 children in the control group (20%) could tolerate hen's egg. CONCLUSIONS: We successfully desensitized 8/10 children with IgE-mediated hen's egg allergy in a 6-month period. The partial outcome in the child who could tolerate 2ml/day reduced the risk of severe reactions after unnoticed introduction of egg. A regular protocol that ensures a daily constant increase of doses helps to reduce possible adverse events, thus improving safety and effectiveness.


Subject(s)
Desensitization, Immunologic/methods , Egg Hypersensitivity/immunology , Egg Proteins/administration & dosage , Eggs/adverse effects , Immunoglobulin E/blood , Administration, Oral , Adolescent , Animals , Chickens , Child , Child, Preschool , Desensitization, Immunologic/adverse effects , Double-Blind Method , Egg Hypersensitivity/diagnosis , Egg Hypersensitivity/etiology , Egg Proteins/adverse effects , Egg Proteins/immunology , Female , Humans , Immune Tolerance , Immunoglobulin E/immunology , Male , Treatment Outcome
2.
PLoS One ; 6(8): e23766, 2011.
Article in English | MEDLINE | ID: mdl-21915243

ABSTRACT

In newborn the innate immune system provides essential protection during primary infections before the generation of an appropriate adaptive immune response that is initially not fully operative. Innate immune response is evoked and perpetuated by molecules derived from microorganisms or by the damage/death of host cells. These are collectively known as damage-associated molecular-pattern (DAMP) molecules. High-mobility group box 1 protein (HMGB1) or amphoterin, which previously was considered to be only a nuclear factor, has been recently identified as a DAMP molecule. When it is actively secreted by inflammatory cells or passively released from necrotic cells, HMGB1 mediates the response to infection, injury and inflammation, inducing dendritic cells maturation and T helper-1-cell responses. To characterize the role of HMGB1 in the innate and immature defense mechanisms in newborns, human cord blood (CB) mononuclear cells, in comparison to adult peripheral blood (PB) mononuclear cells, have been analyzed for its expression. By flow cytometry and western blot analysis, we observed that in CB and PB cells: i) HMGB1 is expressed on cell surface membranes of myeloid dendritic cell precursors, mostly, and lymphocytes (gamma/delta and CD4(+) T cells) to a lesser extent; ii) different pro-inflammatory stimuli or molecules that mimic infection increased cell surface expression of HMGB1 as well as its secretion into extracellular environment; iii) the treatment with synthetic molecules such as aminobisphosphonates (ABs), identified to be γδ T cell antigens, triggered up-regulation of HMGB1 expression on mononuclear cells, as well γδ T lymphocytes, inducing its secretion. The modulation of its secretion and the HMGB1-mediated migration of monocytes indicated HMGB1 as regulator of immune response in an immature system, like CB, through engagement of γδ T lymphocytes and myeloid dendritic cell precursors, essential components of innate immunity. In addition, the increased HMGB1 expression/secretion triggered by ABs, previously characterized for their immuno-modulating and immune-adjuvant capabilities, indicated that immunomodulation might represent a new therapeutical approach for neonatal and adult pathologies.


Subject(s)
Fetal Blood/cytology , Fetal Blood/metabolism , HMGB1 Protein/immunology , HMGB1 Protein/metabolism , Immunity, Innate/drug effects , Immunity, Innate/immunology , Apoptosis/drug effects , Blotting, Western , Cells, Cultured , Chemotaxis, Leukocyte/drug effects , Fetal Blood/immunology , Flow Cytometry , Glyburide/pharmacology , HeLa Cells , Humans , Hypoglycemic Agents/pharmacology , Infant, Newborn , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/drug effects , Microscopy, Confocal , Microscopy, Fluorescence
SELECTION OF CITATIONS
SEARCH DETAIL
...